Results 151 to 160 of about 4,527,801 (246)

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies. [PDF]

MAbs, 2023
Johansson MU, Weinert C, Reichardt DA, Mahler D, Diem D, Hess C, Feusi D, Carnal S, Tietz J, Giezendanner N, Spiga FM, Urech D, Warmuth S.   +12 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

The Phenomenon of Anti-Drug Antibodies in Psoriasis: Mechanisms, Clinical Impact, and Therapeutic Strategies. [PDF]

Int J Mol Sci
Mennella A, Frasca L.
europepmc   +1 more source

Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis. [PDF]

J Allergy Clin Immunol Pract, 2023
Chen ML, Nopsopon T, Akenroye A.
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies. [PDF]

MAbs
Johansson MU, Kerschenmeyer A, Carella A, Carnal S, Schmidt Y, de Felice A, Mahler D, Thomas M, Spiga FM, Tietz J, Weinert C, Hess C, Urech D, Warmuth S.   +13 more
europepmc   +1 more source

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA. [PDF]

Pharmaceutics, 2023
Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, Fernández-Ferreiro A.   +10 more
europepmc   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Identifying Genetic Factors Influencing the Development of Anti-Drug Antibodies in Inflammatory Bowel Disease: A Scoping Review. [PDF]

J Inflamm Res
Culmsee-Holm FB, Buhl E, Kraaer MT, Steenholdt C, Ainsworth MA.   +4 more
europepmc   +1 more source

Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies. [PDF]

Toxicol Pathol, 2022
Adedeji AO, Zhong F, Getz JA, Zhong Z, Halpern W.   +4 more
europepmc   +1 more source